Puma Biotechnology Inc
Most Recent
ASCO 2019 Presentations: Late-Stage Breast Cancer Trials
The annual ASCO (American Society of Clinical Oncology) 2019 meeting will be held on May 31–June 4 in Chicago.
Puma Biotechnology Reduced Guidance for NERLYNX Sales
During its first-quarter earnings conference call, Puma Biotechnology (PBYI) reduced its guidance for fiscal 2019 net sales of NERLYNX in the US market.
Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.
Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.
Chart in Focus: Spectrum Pharmaceuticals’ Financials
In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.
